An Observational, Non-interventional, Multi-center, Chart Review Study Conducted Among Patients Enrolled in an AZD9291 Early Access Program in Hong Kong, With Locally Advanced/Metastatic EGFR T790M Mutation-positive NSCLC and Prior Exposure to EGFR TKI Therapy
Latest Information Update: 16 Dec 2021
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Expanded access; Therapeutic Use
- Sponsors AstraZeneca
Most Recent Events
- 23 Nov 2020 Status changed from active, no longer recruiting to completed.
- 27 Aug 2020 Planned End Date changed from 31 May 2020 to 30 Sep 2020.
- 27 Aug 2020 Planned primary completion date changed from 31 May 2020 to 30 Sep 2020.